A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Siltuximab (Anti IL-6 Monoclonal Antibody) in Patients with High-Risk Smoldering Multiple MyelomaTimothy Brighton, Hartmut Goldschmidt, David Ghez et al.|Blood|2017Cited by 6
PharmaForumDe Zeng, Druck Ausrüstung Kraft-Druck GmbH, Danxia Lin et al.|Oncology Research and Treatment|2017Cited by 1
PharmaNewsDe Zeng, Druck Ausrüstung Kraft-Druck GmbH, Danxia Lin et al.|Oncology Research and Treatment|2017Cited by 0
Society BulletinsDe Zeng, Druck Ausrüstung Kraft-Druck GmbH, Danxia Lin et al.|Oncology Research and Treatment|2017Cited by 0
PharmaForumDe Zeng, Druck Ausrüstung Kraft-Druck GmbH, Danxia Lin et al.|Oncology Research and Treatment|2017Cited by 0